News

ATIR Phase II study is a confirmatory multi-center, proof-of-concept study. Kiadis Pharma CEO Manfred Ruediger said the support from existing and new investors attests to the clinical data

The cyclophilin inhibitors drugs include CicloMulsion and NeuroSTAT which are intended to treat heart reperfusion injury after stenting and traumatic brain injury respectively. Both the products prevent the

As part of the agreement, Canadian urologists will be able to order PCMT through CML HealthCare in early 2013. PCMT by applying mitochondrial DNA analysis to tissue samples

The study compared the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel as the base of an opioid-sparing multimodal regimen

The sublingual once daily medication should be administered from four months prior to the onset of season and continued all through the seasonal period. Paladin Labs interim president

The drug candidate is being studied to treat acquired hemophilia A individuals who developed inhibitory antibodies in opposition to their inborn FVIII. Inspiration considers submitting a biologics license

The CPGR will leverage Affymetrix GeneTitan multi-channel (MC) instrument to offer gene expression and Axiom genotyping services to researchers in the region. CPGR Managing Director Dr Reinhard Hiller

Eliquis 5mg, trade name of apixaban in Europe, is indicated as a twice-daily drug for preventing strokes and systemic embolism in nonvalvular atrial fibrillation (NVAF) adult patients. Oral

The acquired six product lines include Lopressor (metoprolol tartrate USP) excluding Lopressor injection, Lopressor HCT , Lotensin, Lotensin HCT, Parlodel and Methergine. Post acquisition, Validus will be the